Genmab A/S (GMAB.CO)
| Previous close | 1,915.50 |
| Open | 1,919.50 |
| Bid | 1,954.50 x N/A |
| Ask | 1,960.00 x N/A |
| Day's range | 1,919.50 - 1,969.00 |
| 52-week range | 1,825.00 - 2,939.00 |
| Volume | |
| Avg. volume | 129,392 |
| Market cap | 126.757B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 29.58 |
| EPS (TTM) | 66.08 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2,679.62 |
Globe NewswireTransactions in Connection with Share Buy-back Program Genmab
Company Announcement COPENHAGEN, Denmark; April 22, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 15, 2024 to April 19, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announ
GlobeNewswireGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
Company Announcement Net sales of DARZALEX® in the first quarter of 2024 totaled USD 2,692 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 16, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson we
- GlobeNewswire
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; April 8, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 1, 2024 to April 5, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcem
